Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

En Li

Showing results (541-550 of 544) with videos related to

Pageof 55
Sort By:
You have reached the last page of results.This site can display upto 544 results.
Nature Chemical Biology|January 31, 2017
An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EEDWei Qi, Kehao Zhao, Justin Gu, et al.
Journal of Medicinal Chemistry|March 30, 2022
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced MalignanciesYing Huang, Martin Sendzik, Jeff Zhang, et al.
Addiction (Abingdon, England)|November 12, 2023
'No evidence of harm' implies no evidence of safety: Framing the lack of causal evidence in gambling advertising researchPhilip Newall, Youssef Allami, Maira Andrade, et al.
Nature Medicine|October 20, 2015
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug responseHui Gao, Joshua M Korn, Stéphane Ferretti, et al.
Pageof 55

Showing results (541-550 of 544) with videos related to

Sort By:
Pageof 55
You have reached the last page of results.This site can display upto 544 results.
Nature Chemical Biology|January 31, 2017
An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EEDWei Qi, Kehao Zhao, Justin Gu, et al.
Journal of Medicinal Chemistry|March 30, 2022
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced MalignanciesYing Huang, Martin Sendzik, Jeff Zhang, et al.
Addiction (Abingdon, England)|November 12, 2023
'No evidence of harm' implies no evidence of safety: Framing the lack of causal evidence in gambling advertising researchPhilip Newall, Youssef Allami, Maira Andrade, et al.
Nature Medicine|October 20, 2015
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug responseHui Gao, Joshua M Korn, Stéphane Ferretti, et al.
Pageof 55